Edouard Bardou-Jacquet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edouard Bardou-Jacquet has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Louvet
Service des maladies de l'appareil digestif, University Hospital of Lille, Lille, France; Unite INSERM INFINITE, Lille, France
1 shared publication - Antoine Monsel
CHU Pitié-Salpêtrière, AP-HP, Paris, France
1 shared publication - Audrey Coilly
Centre Hépato-Biliaire, hôpital Paul-Brousse AP-HP, Université Paris-Saclay, Inserm U1193, Paris, France
1 shared publication - Baptiste Giguet
Service des maladies du foie, hôpital Pontchaillou, CHU Rennes, Rennes Liver Failure Group RELIEF, Rennes, France
1 shared publication - Bruno Turlin
Department of Pathology, University of Rennes, CHU Rennes, Rennes, France
1 shared publication - Constantine J. Karvellas
Department of Critical Care Medicine, University of Alberta, Edmonton, Canada
1 shared publication
Latest Publications
- Open Access
- 8 September 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Evaluation of available scoring systems in liver transplantation for severe acute-on-chronic liver failure (ACLF)
The Transplantation for ACLF-3 Model (TAM) and Sundaram ACLF-LT-Mortality score (SALT-M) have been proposed to help select liver transplantation (LT) candidates with acute-on-chronic liver failure (ACLF) to optimize post-LT outcomes. We assessed the performance and clinical utility of these scores and their components on a large retrospective international multicenter study. All patients transplanted in the context of ACLF grade 3 (n=336) from 9 international cohorts (2008–2024) were included in the study. The primary endpoint was 1-year post-LT survival. Score discrimination, calibration, and clinical utility using decision-curve (net benefit) analysis were assessed. The 1-year post-LT survival rate was 75.3%. Both TAM (OR 1.91, p =0.0001) and SALT-M (OR 1.09, p 25 (46.9% vs. 78.7%). Respiratory failure (PaO 2 /FiO 2 ≤200) was associated with 1-year post-LT mortality, whereas other variables included in the original scores, diabetes, BMI, and leukocyte count, did not demonstrate significant prognostic value in this cohort. In this large multicenter study, TAM and SALT-M were associated with post-LT mortality but demonstrated limited discriminative accuracy. Candidate high-risk thresholds (TAM ≥3, SALT-M >25) may help identify a small subset of patients with markedly poor post-LT outcomes. However, given their modest performance, these scores should support, not replace, multidisciplinary decision-making, and their applicability should be evaluated in a prospective fashion.
- 8 September 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Open AccessEvaluation of available scoring systems in liver transplantation for severe acute-on-chronic liver failure (ACLF)
The Transplantation for ACLF-3 Model (TAM) and Sundaram ACLF-LT-Mortality score (SALT-M) have been proposed to help select liver transplantation (LT) candidates with acute-on-chronic liver failure (ACLF) to optimize post-LT outcomes. We assessed the performance and clinical utility of these scores and their components on a large retrospective international multicenter study. All patients transplanted in the context of ACLF grade 3 (n=336) from 9 international cohorts (2008–2024) were included in the study. The primary endpoint was 1-year post-LT survival. Score discrimination, calibration, and clinical utility using decision-curve (net benefit) analysis were assessed. The 1-year post-LT survival rate was 75.3%. Both TAM (OR 1.91, p =0.0001) and SALT-M (OR 1.09, p 25 (46.9% vs. 78.7%). Respiratory failure (PaO 2 /FiO 2 ≤200) was associated with 1-year post-LT mortality, whereas other variables included in the original scores, diabetes, BMI, and leukocyte count, did not demonstrate significant prognostic value in this cohort. In this large multicenter study, TAM and SALT-M were associated with post-LT mortality but demonstrated limited discriminative accuracy. Candidate high-risk thresholds (TAM ≥3, SALT-M >25) may help identify a small subset of patients with markedly poor post-LT outcomes. However, given their modest performance, these scores should support, not replace, multidisciplinary decision-making, and their applicability should be evaluated in a prospective fashion.
- Open Access
- 19 May 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (10) , 1799
Artificial Intelligence-Based Opportunities in Liver Pathology—A Systematic Review
Background: Artificial Intelligence (AI)-based Deep Neural Networks (DNNs) can handle a wide range of applications in image analysis, ranging from automated segmentation to diagnostic and prediction. As such, they have revolutionized healthcare, including in the liver pathology field. Objective: The present study aims to provide a systematic review of applications and performances provided by DNN algorithms in liver pathology throughout the Pubmed and Embase databases up to December 2022, for tumoral, metabolic and inflammatory fields. Results: 42 articles were selected and fully reviewed. Each article was evaluated through the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool, highlighting their risks of bias. Conclusions: DNN-based models are well represented in the field of liver pathology, and their applications are diverse. Most studies, however, presented at least one domain with a high risk of bias according to the QUADAS-2 tool. Hence, DNN models in liver pathology present future opportunities and persistent limitations. To our knowledge, this review is the first one solely focused on DNN-based applications in liver pathology, and to evaluate their bias through the lens of the QUADAS2 tool.
- 19 May 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (10) , 1799
Open AccessArtificial Intelligence-Based Opportunities in Liver Pathology—A Systematic Review
Background: Artificial Intelligence (AI)-based Deep Neural Networks (DNNs) can handle a wide range of applications in image analysis, ranging from automated segmentation to diagnostic and prediction. As such, they have revolutionized healthcare, including in the liver pathology field. Objective: The present study aims to provide a systematic review of applications and performances provided by DNN algorithms in liver pathology throughout the Pubmed and Embase databases up to December 2022, for tumoral, metabolic and inflammatory fields. Results: 42 articles were selected and fully reviewed. Each article was evaluated through the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool, highlighting their risks of bias. Conclusions: DNN-based models are well represented in the field of liver pathology, and their applications are diverse. Most studies, however, presented at least one domain with a high risk of bias according to the QUADAS-2 tool. Hence, DNN models in liver pathology present future opportunities and persistent limitations. To our knowledge, this review is the first one solely focused on DNN-based applications in liver pathology, and to evaluate their bias through the lens of the QUADAS2 tool.